Table of Content


List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Metabotropic Glutamate Receptor 5 (GPRC1E or MGLUR5 or GRM5) - Overview
Metabotropic Glutamate Receptor 5 (GPRC1E or MGLUR5 or GRM5) - Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
Products under Development by Universities/Institutes
Metabotropic Glutamate Receptor 5 (GPRC1E or MGLUR5 or GRM5) - Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Metabotropic Glutamate Receptor 5 (GPRC1E or MGLUR5 or GRM5) - Companies Involved in Therapeutics Development
Addex Therapeutics Ltd
Allyx Therapeutics Inc
Appello Pharmaceuticals Inc
Bristol-Myers Squibb Co
Hua Medicine Shanghai Ltd
Laboratorio Farmaceutico CT Srl
Lactocore Inc
Nobias Therapeutics Inc
Noema Pharma AG
Novartis AG
Park of Active Molecules
Tempero Bio
Metabotropic Glutamate Receptor 5 (GPRC1E or MGLUR5 or GRM5) - Drug Profiles
alloswitch-1 - Drug Profile
Product Description
Mechanism Of Action
ALX-001 - Drug Profile
Product Description
Mechanism Of Action
History of Events
AP-612 - Drug Profile
Product Description
Mechanism Of Action
basimglurant - Drug Profile
Product Description
Mechanism Of Action
History of Events
BMS-952048 - Drug Profile
Product Description
Mechanism Of Action
dipraglurant - Drug Profile
Product Description
Mechanism Of Action
History of Events
dipraglurant ER - Drug Profile
Product Description
Mechanism Of Action
dipraglurant IR - Drug Profile
Product Description
Mechanism Of Action
History of Events
GET-73 - Drug Profile
Product Description
Mechanism Of Action
History of Events
HTL-0014242 - Drug Profile
Product Description
Mechanism Of Action
History of Events
LCGM-10 - Drug Profile
Product Description
Mechanism Of Action
mavoglurant - Drug Profile
Product Description
Mechanism Of Action
History of Events
mGLUR5 M - Drug Profile
Product Description
Mechanism Of Action
NB-001 - Drug Profile
Product Description
Mechanism Of Action
History of Events
PAM-12 - Drug Profile
Product Description
Mechanism Of Action
Small Molecules to Agonize mGluR5 for Schizophrenia - Drug Profile
Product Description
Mechanism Of Action
VU-0092273 - Drug Profile
Product Description
Mechanism Of Action
VU-0431316 - Drug Profile
Product Description
Mechanism Of Action
VU-0467558 - Drug Profile
Product Description
Mechanism Of Action
Metabotropic Glutamate Receptor 5 (GPRC1E or MGLUR5 or GRM5) - Dormant Products
Metabotropic Glutamate Receptor 5 (GPRC1E or MGLUR5 or GRM5) - Discontinued Products
Metabotropic Glutamate Receptor 5 (GPRC1E or MGLUR5 or GRM5) - Product Development Milestones
Featured News & Press Releases
Sep 06, 2022: Noema Pharma announces completion of enrollment in the Trigemil Neuralgia Electronic Diary (TNED) validation study
Jun 17, 2022: Addex termites dipraglurant phase 2b/3 study in patients with dyskinesia associated with Parkinson’s disease due to slow recruitment rate
May 27, 2022: Addex provides update on dipraglurant blepharospasm phase 2 feasibility clinical study
Apr 13, 2022: Addex Therapeutics completes patient enrollment for dipraglurant blepharospasm phase 2 clinical study
Feb 22, 2022: Noema Pharma announces first patient dosed in Phase 2b LibraTN study of mGluR5 inhibitor NOE-101 in trigemil neuralgia
Feb 14, 2022: Noema Pharma announces FDA Investigatiol New Drug Authorization for Phase 2b LibraTN study of mGluR5 inhibitor NOE-101 in trigemil neuralgia
Sep 29, 2021: Addex Therapeutics initiates phase 2 clinical study with Dipraglurant in blepharospasm
Jul 07, 2021: Noema Pharma to host a key opinion leader webir on seizures in tuberous sclerosis complex
Jun 29, 2021: Addex Therapeutics initiates pivotal phase 2b/3 study with dipraglurant for dyskinesia associated with Parkinson’s Disease
May 17, 2021: Addex’s Dipraglurant restores syptic plasticity in models of Dystonia
Mar 18, 2020: Addex Therapeutics delays start of Dipraglurant pivotal study and reporting 2019 full year audited results
Jan 17, 2019: Experimental drug improves eye gaze behavior in fragile X syndrome
Dec 13, 2018: Sosei Heptares starts new clinical development program - First subject dosed in Phase I study of HTL0014242, a selective mGlu5 negative allosteric modulator in development to treat psychiatric and neurological disorders
Oct 18, 2017: Van Leeuwenhoeck Issues Initiation of Coverage Research Report on Addex Therapeutics and Estimated ADXN Share Price of CHF 11.5 per Share
Feb 06, 2017: Addex’s Clinical Programs and Discovery Platform Highlighted in Review of Allosteric Modulators for the Treatment of Neurodegenerative Diseases
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer



List of Figures

List of Figures
Number of Products under Development by Stage of Development, 2022
Number of Products under Development by Therapy Areas, 2022
Number of Products under Development by Top 10 Indications, 2022
Number of Products by Mechanism of Actions, 2022
Number of Products by Stage and Mechanism of Actions, 2022
Number of Products by Stage and Route of Administration, 2022
Number of Products by Molecule Types, 2022
Number of Products by Stage and Molecule Types, 2022

List of Tables

List of Tables
Number of Products under Development by Stage of Development, 2022
Number of Products under Development by Therapy Areas, 2022
Number of Products under Development by Indications, 2022
Number of Products under Development by Indications, 2022 (Contd..1)
Number of Products under Development by Companies, 2022
Products under Development by Companies, 2022
Products under Development by Companies, 2022 (Contd..1)
Number of Products under Investigation by Universities/Institutes, 2022
Products under Investigation by Universities/Institutes, 2022
Number of Products by Stage and Mechanism of Actions, 2022
Number of Products by Stage and Route of Administration, 2022
Number of Products by Stage and Molecule Type, 2022
Pipeline by Addex Therapeutics Ltd, 2022
Pipeline by Allyx Therapeutics Inc, 2022
Pipeline by Appello Pharmaceuticals Inc, 2022
Pipeline by Bristol-Myers Squibb Co, 2022
Pipeline by Hua Medicine Shanghai Ltd, 2022
Pipeline by Laboratorio Farmaceutico CT Srl, 2022
Pipeline by Lactocore Inc, 2022
Pipeline by Nobias Therapeutics Inc, 2022
Pipeline by Noema Pharma AG, 2022
Pipeline by Novartis AG, 2022
Pipeline by Park of Active Molecules, 2022
Pipeline by Tempero Bio, 2022
Dormant Products, 2022
Dormant Products, 2022 (Contd..1)
Dormant Products, 2022 (Contd..2)
Dormant Products, 2022 (Contd..3)
Discontinued Products, 2022
Discontinued Products, 2022 (Contd..1)